Compare Core Scientific Inc (CORZ) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Davita Inc — how do they compare? Core Scientific Inc trades at $22.22 (market cap $7.22B), while Davita Inc trades at $232 (market cap $15.12B). The key difference: Davita Inc is far larger — about 2.1× Core Scientific Inc's market cap, and Davita Inc is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.
| CORZ | DVA | |
|---|---|---|
Market Cap | $7.22B | $15.12B |
Sector | Technology | Health |
52-Week High | $29.16 | $235.71 |
52-Week Low | $12.65 | $103.87 |
Enterprise Value | $8.27B | $27.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $22.71, down 3.32% amid bearish technical signals despite strong analyst support. The company is transitioning from Bitcoin mining to AI data center operations, with Q1 2026 colocation revenue surging to $77.5M. However, fundamentals show deep losses with a -341.68% net income margin and negative cash flow of -$525.6M in 2025, though 2026 projections indicate improved operating cash flow of $573M.
The stock presents a high-risk, high-reward opportunity with Wall Street consensus bullish (86% buy ratings) and a $34.17 price target representing 50% upside. Key risks include persistent cash burn, execution challenges in the AI pivot, and power grid reliability concerns in Texas. The company's success hinges on converting its multi-gigawatt power pipeline into profitable AI infrastructure contracts.
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
